CCF Funding Part of Important Study and Publication
Nabeel M. Bardeesy, PhD is the John R. Gallagher III and Katherine A. Gallagher Endowed Chair in Gastrointestinal Cancer Research at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. He has worked with CCF in multiple capacities, and is a Science and Medical Advisory Board emeritus member, and is currently participating in the Cure Cholangiocarcinoma Think Tank (C2T2).
He leads the Bardeesy Lab at MGH’s Krantz Family Center for Cancer Research and he and his team of experts just published “Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity” in Science Magazine. Getting work on a rare cancer published in Science Magazine is a significant achievement for basic scientists because it not only highlights the groundbreaking nature and high quality of their research but also brings critical attention and validation to understudied diseases, potentially accelerating advancements in understanding and treatment.
Investing in research is vital, and CCF is proud this study was funded partly through the C2T2, the CCF Collaboration Award, and the CCF Christopher J. Wilke Memorial and Kathleen and Paul Sidenblad Research Fellowships. The Cholangiocarcinoma Foundation Research Fellowship Program is aimed at supporting early-career researchers focusing on studies in cholangiocarcinoma. Since 2015, the Foundation has awarded 60 Research Fellowships totaling $3.1 million in seed funding to raise awareness about cholangiocarcinoma and inspire innovative, high-quality research. Learn more about the Fellowship recipients here.
The funding CCF donors provide kick-start projects that produce good data and results and attract further investment from bigger funding sources like federal or private foundation grants, leading to significant discoveries, publications, and collaborative opportunities. A publication like this shows this in action.